Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Not a member yet
3661 research outputs found
Sort by
Humoral immune response of pigs infected with Toxocara cati
No full textFil: Sierra, Maria Florencia. Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Salud Pública; Argentina.Fil: Ricoy, Gerardo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología. Servicio inmunología parasitaria; Argentina.Fil: Sosa, Sonia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología. Servicio inmunología parasitaria; Argentina.Fil: Colavecchia, Silvia Beatriz. Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Inmunología; Argentina.Fil: Santillan, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología. Servicio inmunología parasitaria; Argentina.Fil: López, Clara Maria. Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Salud Pública; Argentina.Fil: Mundo, Silvia Leonor. Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Inmunología; Argentina.Fil: Sommerfelt, I E. Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Salud Pública; Argentina.Toxocara cati is one of the causative agents of human toxocariasis. Serological methods are used for diagnosis in paratenic hosts like humans but the humoral immune response triggered by this parasite is unknown. We characterized the humoral immune response to T. cati excretory-secretory antigens (TES) in pigs as animal model during the acute and chronic stages of infection. ELISA and Western Blot techniques were used to determine antibody response. Pigs were experimentally inoculated with 100,000 infective Toxocara cati eggs. Blood was collected at 7, 14, 21 and 28 days post-inoculation (d.p.i.) to assess the acute stage of infection and 90, 120 and 180 d. p.i. for chronic stage analysis. ELISA showed values higher than the cut-off of specific IgM and IgG at 7 d. p.i. with significant differences at 0 and 7 d. p.i. for IgM and at 14, 21 and 28 d. p.i. for IgG in the acute stage. Higher and stable levels were detected in the chronic stage. Western Blot showed bands from 102 to 38 kDa detected by specific IgM and IgG. More immunogenic bands were identified by specific IgG. In the chronic stage of infection a band near 31 kDa was the only band detected by IgM until 150 d. p.i. Specific IgG recognized bands between 102 and 31 kDa. This study demonstrates how the humoral immune response evolves in the acute and chronic stages of infection and provides evidence on the role of the pig as a paratenic host of T. cati
Evolução do desempenho dos Laboratórios de Referência na América Latina na detecção de mecanismos de resistência antimicrobiana
No full textFil: Gagetti, Paula. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Pasteran, Fernando. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Ceriana, Paola.ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Prieto, Mónica. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio de Bacteriología Especial; Argentina.Fil: Cipolla, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Tuduri, Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Bruinsma, Nienke. Antimicrobial Resistance Program, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization WashingtonDC; Estados Unidos.Fil: Galas, Marcelo Antimicrobial Resistance Program, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization WashingtonDC; Estados Unidos.Fil: Ramón-Pardo, Pilar. Antimicrobial Resistance Program, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization WashingtonDC; Estados Unidos.Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.The objective is to present the results of the Latin American Program for Quality Assurance in Bacteriology and Antimicrobial Resistance (LA-EQAS) between 2000 and 2018 and the evolution of the detection of resistance mechanisms with clinical impact
A combined approach of MALDI-TOF mass spectrometry and multivariate analysis as a potential tool for the detection of SARS-CoV-2 virus in nasopharyngeal swabs
Get PDFFil: Rocca, María Florencia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Zintgraff, Jonathan Cristian. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Dattero, María Elena. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología; Argentina.Fil: Silva Santos, Leonardo. Instituto de Química de Recursos Naturales, Universidad de Talca; Chile.Fil: Ledesma, Martín. Red Nacional de Espectrometría de Masas aplicada a la Microbiología Clínica (ReNaEM Argentina), Argentina; Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires; ArgentinaFil: Vay, Carlos. Red Nacional de Espectrometría de Masas aplicada a la Microbiología Clínica (ReNaEM Argentina), Argentina; Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires; ArgentinaFil: Prieto, Mónica. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Benedetti, Estefanía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología; Argentina. ,Fil: Avaro, Martín. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología; Argentina.Fil: Russo, Mara. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología; Argentina.Fil: Nachtigall, Fabiane Manke. Instituto de Ciencias Químicas Aplicadas, Universidad Autónoma de Chile; Chile.Fil: Baumeister, Elsa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología; Argentina.Coronavirus disease 2019, known as COVID-19, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The early, sensitive and specific detection of SARS-CoV-2 virus is widely recognized as the critical point in responding to the ongoing outbreak. Currently, the diagnosis is based on molecular real time RT-PCR techniques, although their implementation is being threatened due to the extraordinary demand for supplies worldwide. That is why the development of alternative and / or complementary tests becomes so relevant. Here, we exploit the potential of mass spectrometry technology combined with machine learning algorithms, for the detection of COVID-19 positive and negative protein profiles directly from nasopharyngeal swabs samples. According to the preliminary results obtained, accuracy = 67.66 %, sensitivity = 61.76 %, specificity = 71.72 %, and although these parameters still need to be improved to be used as a screening technique, mass spectrometry-based methods coupled with multivariate analysis showed that it is an interesting tool that deserves to be explored as a complementary diagnostic approach due to the low cost and fast performance. However, further steps, such as the analysis of a large number of samples, should be taken in consideration to determine the applicability of the method developed
Use of the PCR in a Combined Methodological Approach for the Study of Human Fascioliasis in an Endemic Area
Get PDFFil: Carnevale, Silvana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Malandrini, Jorge Bruno. Universidad Nacional de Catamarca. Facultad de Ciencias de la Salud; Argentina.Fil: Pantano, María Laura. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Sawicki, Mirna. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina.Fil: Kamenetzky, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Microbiología y Parasitología Médica; Argentina.Fil: Soria, Claudia Cecilia. Universidad Nacional de Catamarca. Facultad de Ciencias de la Salud; Argentina.Fil: Velásquez, Jorge Néstor. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina.Purpose: Fascioliasis is a worldwide distributed trematodiasis considered a neglected disease. Diagnosis in humans has been traditionally based on parasitological and immunological techniques. Recently we reported the use of the PCR in stool samples for the individual diagnosis. The purpose of this study was to evaluate human fascioliasis by a combination of diagnostic methods in an area where the disease is highly endemic in animals.
Methods: We studied all the inhabitants (N = 240) of Tatón village, Argentina, by Fasciola hepatica rproCL1-ELISA. Among them, we continued the study with 13 cases that had at least two positive serological tests, who performed a questionnaire, physical examination, abdominal ultrasonography, and collection of blood and faeces. Blood/serum samples were used for Fh rproCL1-ELISA and liver function tests. Faeces were used for parasitological analysis and PCR of a repetitive fragment of Fasciola sp.
Results: Among the 13 patients, 9 presented symptoms of biliary colic. All patients repeated positive serology. F. hepatica eggs were not detected. PCR was positive in 11 cases.
Conclusion: This is the first report employing an approach based on the combination of methods for the evaluation of human fascioliasis in an endemic area, which includes molecular tools with a high value in detecting low infections
In Silico guided discovery of Novel Class I and II Trypanosoma cruzi Epitopes recognized by T Cells from Chagas' disease patients
Get PDFFil: Acevedo, Gonzalo R. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Juiz, Natalia A. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Ziblat, Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental; Argentina.Fil: Pérez Perri, Lucas. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Girard, Magalí C. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Ossowski, Micaela S. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Fernández, Marisa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Hernández, Yolanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Chadi, Raúl. Hospital General de Agudos Dr. Ignacio Pirovano; Argentina.Fil: Wittig, Michael. Christian-Albrechts-University of Kiel. Institute of Clinical Molecular Biology; Alemania.Fil: Franke, Andre. Christian-Albrechts-University of Kiel. Institute of Clinical Molecular Biology; Alemania.Fil: Nielsen, Morten. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Biotecnológicas; Argentina.Fil: Gómez, Karina A. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.T cell-mediated immune response plays a crucial role in controlling Trypanosoma cruzi infection and parasite burden, but it is also involved in the clinical onset and progression of chronic Chagas' disease. Therefore, the study of T cells is central to the understanding of the immune response against the parasite and its implications for the infected organism. The complexity of the parasite-host interactions hampers the identification and characterization of T cell-activating epitopes. We approached this issue by combining in silico and in vitro methods to interrogate patients' T cells specificity. Fifty T. cruzi peptides predicted to bind a broad range of class I and II HLA molecules were selected for in vitro screening against PBMC samples from a cohort of chronic Chagas' disease patients, using IFN-γ secretion as a readout. Seven of these peptides were shown to activate this type of T cell response, and four out of these contain class I and II epitopes that, to our knowledge, are first described in this study. The remaining three contain sequences that had been previously demonstrated to induce CD8+ T cell response in Chagas' disease patients, or bind HLA-A*02:01, but are, in this study, demonstrated to engage CD4+ T cells. We also assessed the degree of differentiation of activated T cells and looked into the HLA variants that might restrict the recognition of these peptides in the context of human T. cruzi infection
GJB2 and GJB6 Genetic Variant Curation in an Argentinean Non-Syndromic Hearing-Impaired Cohort
No full textFil: Buonfiglio, Paula. Consejo Nacional de Investigaciones Científicas y Técnicas-INGEBI/CONICET. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres". Laboratorio de Fisiología y Genética de la Audición, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Bruque, Carlos D. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica; Argentina.Fil: Luce, Leonela. Universidad de Buenos Aires. Cátedra de Genética, Facultad de Farmacia y Bioquímica. Laboratorio de Distrofinopatías, Ciudad Autónoma de Buenos Aires; Argentina. Universidad de Buenos Aires. Instituto de Inmunología, Genética y Metabolismo-INIGEM/CONICET, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Giliberto, Florencia. Universidad de Buenos Aires. Cátedra de Genética, Facultad de Farmacia y Bioquímica. Laboratorio de Distrofinopatías, Ciudad Autónoma de Buenos Aires; Argentina. Universidad de Buenos Aires. Instituto de Inmunología, Genética y Metabolismo-INIGEM/CONICET, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Lotersztein, Vanesa. Hospital Militar Central "Dr. Cosme Argerich". Servicio de Genética, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Menazzi, Sebastián. Hospital de Clínicas "José de San Martín". Servicio de Genética, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Paoli, Bibiana. Hospital de Clínicas "José de San Martín". Servicio de Otorrinolaringología Infantil, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Elgoyhen, Ana Belén. Consejo Nacional de Investigaciones Científicas y Técnicas-INGEBI/CONICET. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres". Laboratorio de Fisiología y Genética de la Audición, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Dalamón, Viviana. Consejo Nacional de Investigaciones Científicas y Técnicas-INGEBI/CONICET. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres". Laboratorio de Fisiología y Genética de la Audición, Ciudad Autónoma de Buenos Aires; Argentina.Genetic variants in GJB2 and GJB6 genes are the most frequent causes of hereditary hearing loss among several deaf populations worldwide. Molecular diagnosis enables proper genetic counseling and medical prognosis to patients. In this study, we present an update of testing results in a cohort of Argentinean non-syndromic hearing-impaired individuals. A total of 48 different sequence variants were detected in genomic DNA from patients referred to our laboratory. They were manually curated and classified based on the American College of Medical Genetics and Genomics/Association for Molecular Pathology ACMG/AMP standards and hearing-loss-gene-specific criteria of the ClinGen Hearing Loss Expert Panel. More than 50% of sequence variants were reclassified from their previous categorization in ClinVar. These results provide an accurately interpreted set of variants to be taken into account by clinicians and the scientific community, and hence, aid the precise genetic counseling to patients
Antifungal Activity of Essential Oils Against Candida Species Isolated from Clinical Samples
Get PDFFil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento Micología; Argentina.Fil: Vivor, W. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento Micología; Argentina.Fil: Szusz, W. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento Micología; Argentina.Fil: Albo, G. Universidad Nacional de La Plata. Facultad de Ciencias Agrarias y Forestales; Argentina.We evaluated the in vitro antifungal activity of essential oils obtained from the aromatic plants Laurus nobilis, Thymus vulgaris, Mentha piperita, Cymbopogon citratus and Lippia junelliana against the following Candida species isolated from clinical samples: C. krusei (n = 10); C. albicans (n = 50); C. glabrata (n = 70) and C. parapsilosis (n = 80). The minimal inhibitory concentration (MIC) was determined according to EDef 7.3.1 document from EUCAST. Amphotericin B and fluconazole were the antifungal drugs used as inhibition control. The concentration ranges evaluated were 0.4-800 and 0.03-128 mg l-1 for essential oils and antifungal drugs, respectively. MIC50 and MIC90, mode and ranges were calculated. All the Candida spp. evaluated were susceptible to amphotericin B (MIC ≤ 1 mg l-1), while fluconazole was inactive for C. krusei (MIC ≥ 32 mg l-1) and intermediate for C. glabrata (MIC≤ 32 mg l-1). The essential oils showed antifungal activity on Candida spp. tested with MIC90 values ranging from 0.8 to 800 mg l-1. In general, the most active essential oils were L. nobilis and T. vulgaris (MIC90 0.8-0.16 mg l-1), and the least active was C. officinalis (MIC90 400-800 mg l-1). C. krusei was inhibited by 5/6 of the essential oils evaluated, and C. glabrata was the least susceptible one. This in vitro study confirms the antifungal activity of these six essential oils assayed which could be a potential source of new molecules useful to control fungal infections caused by some Candida species, including those resistant to antifungal drugs
Multimethodological Approach to Gastrointestinal Microsporidiosis in HIV-Infected Patients
No full textFil: Velásquez,Jorge Néstor. Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autónoma de Buenos Aires; Argentina.Fil: di Risio, Cecilia. Hospital General de Agudos J. M. Penna, Ciudad Autónoma de Buenos Aires; Argentina. ,Fil: Etchart, Cristina. Hospital General de Agudos J. M. Penna, Ciudad Autónoma de Buenos Aires; Argentina.Fil: Chertcoff, Agustín Víctor. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Astudillo, Osvaldo Germán. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Carnevale, Silvana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Purpose
Microsporidiosis is an opportunistic infection that produces chronic diarrhoea and cholangiopathy in patients with AIDS, mainly caused by two species of microsporidia, Enterocytozoon bieneusi and Encephalitozon intestinalis. The aim of this work was to develop an integral system for the diagnosis of microsporidiosis of the intestine and biliary tract in HIV-infected patients, comprising microscopic and molecular techniques.
Methods
The study population comprised 143 adult patients of both sexes with diagnosis of HIV infection, with chronic diarrhoea, and with or without HIV-associated cholangiopathy. Stool studies for microsporidia identification of spores were performed on each patient. A video esofagogastroduodenoscopy with biopsy collection was also carried out for routine histology and semi-thin sections stained with Azure II. Species identification was carried out by transmission electron microscopy and/or polymerase chain reaction for the species E. bieneusi and E. intestinalis.
Results
Out of the 143 patients a total of 12.6% (n = 18) were infected with microsporidia. Microsporidia species identified in most cases was E. bieneusi (16/18 cases), followed by E. intestinalis (4/18), all of these last ones in coinfection with E. bieneusi.
Conclusions
Clinical, imaging, microscopic and molecular analyses, when applied in a systematic and integrated approach, allow diagnosis and identification of microsporidia at species level in AIDS patients with chronic diarrhoea, and with or without HIV-associated cholangiopathy
Serum Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome
No full textFil: Maleki, Kimia T. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm; Suecia.Fil: García, Marina. Laboratorio de Inmunología de Enfermedades Respiratorias, Instituto de Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina; Argentina.Fil: Iglesias, Ayelén. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Biología Molecular; Argentina.Fil: Alonso, Daniel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Biología Molecular; Argentina.Fil: Ciancaglini, Matías. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Biología Molecular; Argentina.Fil: Hammar, Ulf. Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm; Suecia.Fil: Ljunggren, Hans-Gustaf. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm; Suecia.Fil: Schierloh, Pablo. Laboratorio de Microscopía Aplicada a Estudios Moleculares y Celulares, Instituto de Investigación y Desarrollo en Bioingeniería y Bioinformática, CONICET, Facultad de Ingeniería, Universidad Nacional de Entre Ríos; Argentina.Fil: Martínez, Valeria P. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Biología Molecular; Argentina.Fil: Klingström, Jonas. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm; Suecia.Hantavirus pulmonary syndrome (HPS) is caused by Andes virus (ANDV) and related hantaviruses in the Americas. Despite a fatality rate of 40%, the pathogenesis of HPS is poorly understood and factors associated with severity, fatality, and survival remain elusive